Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Orthopedic Laboratory of Chongqing Medical University, Chongqing, People's Republic of China.
J Orthop Surg Res. 2021 Dec 28;16(1):738. doi: 10.1186/s13018-021-02888-3.
In recent years, numerous investigations have been conducted to determine the clinical significance and critical functions of vascular endothelial growth factor (VEGF) in various malignant cancers. The purpose of this meta-analysis was to comprehensively evaluate the prognostic and clinicopathological value of VEGF in patients with osteosarcoma.
We performed a systematic literature retrieval of available databases. Odds ratios (ORs) or standard mean difference (SMD) for clinicopathological parameters, hazard ratios (HRs) for overall survival and disease-free survival were calculated to assess the correlation between VEGF expression and prognosis in patients with osteosarcoma.
A total of 22 studies with 1144 patients were included in our study. Pooled analyses showed that VEGF overexpression predicted worse overall survival (HR, 2.42; 95% CI, 1.87-3.11, p < 0.001) and disease-free survival (HR, 2.604; 95% CI, 1.698-3.995, p < 0.001), respectively. Furthermore, investigation regarding osteosarcoma clinicopathologic characteristics suggested that high VEGF expression was significantly associated with metastasis (OR, 4.39; 95% CI, 2.77-6.95; p < 0.001), clinical stage (OR, 0.73; 95% CI, 0.62-0.87; p < 0.001), and microvessel density (SMD, 3.33, 95% CI,1.57-5.10, p < 0.001), but not associated with tumor location, gender, age, local recurrence, and chemotherapy response.
Our meta-analysis findings suggest that elevated VEGF expression may be a predictive biomarker for poor prognosis and adverse clinicopathological characteristics in patients with osteosarcoma.
近年来，大量研究旨在确定血管内皮生长因子（VEGF）在各种恶性肿瘤中的临床意义和关键功能。本荟萃分析的目的是全面评估 VEGF 在骨肉瘤患者中的预后和临床病理价值。
我们对现有数据库进行了系统的文献检索。使用优势比（OR）或标准均数差（SMD）评估临床病理参数，使用风险比（HR）评估总生存率和无病生存率，以评估 VEGF 表达与骨肉瘤患者预后之间的相关性。
共有 22 项研究，共纳入 1144 例患者。荟萃分析显示，VEGF 过表达预测总生存率（HR，2.42；95%CI，1.87-3.11，p<0.001）和无病生存率（HR，2.604；95%CI，1.698-3.995，p<0.001）均更差。此外，对骨肉瘤临床病理特征的研究表明，VEGF 高表达与转移（OR，4.39；95%CI，2.77-6.95；p<0.001）、临床分期（OR，0.73；95%CI，0.62-0.87；p<0.001）和微血管密度（SMD，3.33，95%CI，1.57-5.10，p<0.001）显著相关，与肿瘤位置、性别、年龄、局部复发和化疗反应无关。
本荟萃分析结果表明，VEGF 表达升高可能是骨肉瘤患者预后不良和临床病理特征不良的预测生物标志物。
